Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases

Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD006988. doi: 10.1002/14651858.CD006988.pub2.

Abstract

Background: Differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases has been observed in follow-up studies. The management of this condition remains controversial. Most studies support blind radioactive iodine treatment while others negate this approach.

Objectives: To assess the effects of radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

Search strategy: Studies were obtained from computerised searches of MEDLINE, EMBASE, The Cochrane Library, China National Infrastructure (CNKI) and paper collections of conferences held in Chinese.

Selection criteria: Randomised controlled clinical trials and prospective controlled clinical trials.

Data collection and analysis: Two authors independently extracted data and interviewed authors of all potentially relevant studies by electronic mail to verify randomisation procedures. One author entered data into a data extraction form and the second one verified the results of this procedure.

Main results: Because of the absence of any suitable randomised or prospective controlled trial in this area, results currently cannot be presented.

Authors' conclusions: The currently available evidence is insufficient to reliably assess the potential of radioiodine treatment for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases.

Publication types

  • Review
  • Systematic Review

MeSH terms

  • Biomarkers, Tumor / blood*
  • Humans
  • Iodine Radioisotopes / therapeutic use*
  • Thyroglobulin / blood*
  • Thyroid Neoplasms / blood
  • Thyroid Neoplasms / radiotherapy*

Substances

  • Biomarkers, Tumor
  • Iodine Radioisotopes
  • Thyroglobulin